Daily close, T-120 (4/21/25) through T+5. Run-up high $21.25 on 10/2/25, low $12.94 on 4/21/25 (T-120 to T-1). FDA decision 10/6/25. Historical price action, not a forecast.
Positioning before the decision
On Sep 22, 2025, 14 days before the decision date, at-the-money options priced a move of ±12.3% through Oct 17, 2025 (the first listed expiry after the decision; ATM implied volatility 59%). The stock closed -0.8% at the first close across the decision and +0.7% five trading days on. A straddle priced weeks out covers ordinary movement plus the event, so this is the move the options market priced through that expiry, not the event-implied move alone. How this compares across 1,000+ decisions.
Decision facts
FDA decision date2025-10-06
DrugZORYVE (roflumilast) Cream 0.05%
IndicationAtopic Dermatitis - ages of 2-5 years old
Was ZORYVE (roflumilast) Cream 0.05% approved by the FDA?
Yes. The FDA approved the application for ZORYVE (roflumilast) Cream 0.05% on October 6, 2025. The primary source is linked on this page.
What was ZORYVE (roflumilast) Cream 0.05% under FDA review for?
The application covered Atopic Dermatitis - ages of 2-5 years old. The FDA approved the application on October 6, 2025.
How did ARQT stock react to the FDA decision?
On the decision day ARQT moved -0.8%. That is the recorded reaction to this specific event -- historical measurement, not a prediction, and not investment advice.